Labcorp (LH)
NYSEHealth CareMedical - Diagnostics & ResearchSnapshot 2026-11-05
$363.30-1.22%
Close 2026-11-05 · 1-day change
NYSEHealth CareMedical - Diagnostics & ResearchSnapshot 2026-11-05
QuarterlyIQ Insights · LH
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How this business ranks within health care on a research-validated quality screen. As of 2026-11-05.
The screen ranks LH against its sector on four durable signals: share dilution, return on capital, free-cash-flow yield, and FCF margin. Historically the highest-quality names tended toward better typical outcomes and fewer bad years over multi-year holds (strongest at three years, modest at one), and that pattern showed up even before the price moved. It characterizes business quality, not price direction.
Each leg is a sector-relative percentile (higher is better); 4 of 4 legs were available for this name. The composite is built from these four; the raw value follows each percentile for context.
A forward quality tilt, not a price prediction, and context for your own research rather than a recommendation. Not investment advice.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated strong grew net income 53% of the time over the next year (vs 42% for the rest of the cohort, n=10089).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Labcorp also remains committed to a disciplined allocation of capital.
Stated in 7 of 8 supplied quarters. Management reported: “In the third quarter of 2026, the company invested $255.5 million in acquisitions and paid out $58.2 million in dividends.” “The company has $1.4 billion remaining under its board-authorized share repurchase program, providing continued flexibility to return capital to shareholders.”
“Labcorp also remains committed to a disciplined allocation of capital.”
“2 Labcorp also remains committed to a disciplined allocation of capital.”
“Labcorp also remains committed to a disciplined allocation of capital.”
“• Announced a strategic investment to build a new state-of-the-art 500,000 square foot Central Laboratory facility in Indiana, with construction expected to begin later in 2026.”
“Enterprise level guidance includes the estimated impact from currently anticipated capital allocation, including acquisitions, share repurchases and dividends.”
“Enterprise level guidance includes the estimated impact from currently anticipated capital allocation, including acquisitions, share repurchases and dividends.”
“Enterprise level guidance includes the estimated impact from currently anticipated capital allocation, including acquisitions, share repurchases and dividends.”
Be the partner of choice for health systems and leading pharmaceutical companies: • Acquired MLM Medical Labs, a leading global central and specialty laboratory provider with operations across the Un…
Stated in 7 of 8 supplied quarters. Management reported: “Be the partner of choice for health systems and leading pharmaceutical companies: • Acquired MLM Medical Labs, a leading global central and specialty laboratory provider with operations across the United States, Germany and South Africa.” “• Subsequent to quarter end, signed the following three acquisition agreements; the timing of each of these is subject to regulatory approvals and customary closing conditions: ◦ an agreement to acquire select assets of BioReference Health’s laboratory testing businesses focused on clinical and women’s health testing services, urology, corrections and certain operational assets.” Revenue was $3.810 billion in 2026-Q3.
1 Labcorp continues to advance its strategic priorities: Lead in specialty testing: • Received FDA approval of PGDx elio® tissue complete CDx as a companion diagnostic to help identify patients with…
Stated in 7 of 8 supplied quarters. Management reported: “1 Labcorp continues to advance its strategic priorities: Lead in specialty testing: • Received FDA approval of PGDx elio® tissue complete CDx as a companion diagnostic to help identify patients with advanced melanoma.” “• Subsequent to the quarter: ◦ launched the FDA-cleared Elecsys® pTau-217 blood test, expanding access to Alzheimer's disease testing in both primary and specialty care settings.”
Shape our future through technology and innovation: • Announced enhancements to Labcorp Global Trial Connect™, including new capabilities across the Labcorp Sponsor™ and Labcorp Investigator™ portal…
Stated in 7 of 8 supplied quarters. Management reported: “Shape our future through technology and innovation: • Announced enhancements to Labcorp Global Trial Connect™, including new capabilities across the Labcorp Sponsor™ and Labcorp Investigator™ portal experiences.” “Shape our future through technology and innovation: • Launched an AI-powered, real-world data platform with Amazon Web Services (AWS) and Datavant to accelerate Alzheimer’s research.”
2 Drive personalized health solutions: • Expanded the Labcorp OnDemand test menu, including the launch of our Advanced Health Panel and the Marker by Labcorp™ Genetic Health Panel.
Stated in 4 of 8 supplied quarters. Management reported: “2 Drive personalized health solutions: • Expanded the Labcorp OnDemand test menu, including the launch of our Advanced Health Panel and the Marker by Labcorp™ Genetic Health Panel.” “The OnDemand portfolio now has over 140 panels and tests.”
“2 Drive personalized health solutions: • Expanded the Labcorp OnDemand test menu, including the launch of our Advanced Health Panel and the Marker by Labcorp™ Genetic Health Panel.”
Over the trailing year it converted 1.38x of net income into operating cash flow. Historically, Health Care names rated neutral grew net income 52% of the time over the next year (vs 44% for the rest of the cohort, n=3371).
Not enough signal yet.
Not enough signal to read sensitivity to the US dollar, the broad stock market, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity (low R² over the window).
23 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated volatile grew net income 45% of the time over the next year (vs 45% for the rest of the cohort, n=10076).
Not investment advice. As of 2026-11-05.
“Be the partner of choice for health systems and leading pharmaceutical companies: • Acquired MLM Medical Labs, a leading global central and specialty laboratory provider with operations across the Un…”
“Be a partner of choice for health systems and regional/local laboratories: • Awarded once again a Department of Defense contract to provide laboratory testing for service members and their families a…”
“1 Labcorp continues to advance its strategic priorities: Be a partner of choice for health systems and regional and local laboratories: • Announced a nationwide strategic collaboration with Children’…”
“1 In the fourth quarter of 2025, Labcorp advanced its position as a partner of choice for health systems and regional/local laboratories, expanding access to Labcorp’s broad menu of routine and speci…”
“1 Labcorp advanced its position as a partner of choice for health systems and regional/local laboratories.”
“1 In the second quarter, Labcorp advanced its position as a partner of choice for hospitals, health systems and regional/local laboratories: • Announced an agreement to acquire select assets of Incyt…”
“1 In the first quarter, Labcorp advanced its position as a partner of choice for hospitals, health systems and regional/local laboratories: • Entered into a strategic collaboration with New Jersey-ba…”
“1 Labcorp continues to advance its strategic priorities: Lead in specialty testing: • Received FDA approval of PGDx elio® tissue complete CDx as a companion diagnostic to help identify patients with…”
“1 Labcorp continues to advance its strategic priorities: Lead in specialty testing, with several advancements in Labcorp Oncology: • Added an advanced DPYD genotyping test that helps identify patient…”
“Lead in specialty testing: • Announced a collaboration with Illumina to expand access to advanced genomic testing in oncology to deliver more precise biomarker insights.”
“Document FOR IMMEDIATE RELEASE Media Investors Neil Hirsch Christin O’Donnell Media@labcorp.com Investor@labcorp.com Labcorp Announces 2025 Fourth Quarter and Full Year Results Company Provides 2026…”
“Document FOR IMMEDIATE RELEASE Media Investors Neil Hirsch Christin O’Donnell Media@labcorp.com Investor@labcorp.com Labcorp Announces 2025 Third Quarter Results Updates Full-Year Guidance • Financia…”
“Document FOR IMMEDIATE RELEASE Media Investors Neil Hirsch Christin O’Donnell Media@labcorp.com Investor@labcorp.com Labcorp Announces 2025 Second Quarter Results Raises Full-Year Guidance • Financia…”
“Document FOR IMMEDIATE RELEASE Media Investors Neil Hirsch Christin Odonnell Media@labcorp.com Investor@labcorp.com Labcorp Announces 2025 First Quarter Results Updates Full-Year Guidance • Results f…”
“Shape our future through technology and innovation: • Announced enhancements to Labcorp Global Trial Connect™, including new capabilities across the Labcorp Sponsor™ and Labcorp Investigator™ portal…”
“Shape our future through technology and innovation: • Expanded a collaboration with Epic to place 6,500-plus diagnostic tests on Epic’s Aura platform.”
“Shape our future through technology and innovation: • Launched an AI-powered, real-world data platform with Amazon Web Services (AWS) and Datavant to accelerate Alzheimer’s research.”
“The company also continued to incorporate the power of science, technology and innovation across the organization.”
“Labcorp also continued to incorporate the power of science, innovation and technology across the organization during or subsequent to the quarter: • Expanded its oncology portfolio with key launches…”
“Labcorp also continued to incorporate the power of science, innovation and advanced technology across the organization during or subsequent to the quarter: • Introduced Labcorp® Plasma Complete, a gr…”
“Additionally, we strengthened our presence in key high growth areas including oncology, women’s health, neurology and autoimmune disease.”
“Grow Consumer Health : • Announced the Marker by Labcorp Genetic Health Panel through Labcorp OnDemand where consumers can get their biomarker and genetic testing and insights from a single source.”
“Drive personalized health solutions: • Grew Consumer Health and expanded the Labcorp OnDemand test portfolio with new tests for insulin resistance and pancreatic function, as well as customizable men…”
“• Expanded its consumer offerings by launching several consumer-initiated tests through Labcorp OnDemand, including tests that measure an individual’s cortisol and leptin levels, and introducing a ne…”